You are viewing: Mexico Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Mexico Plasma Fractionation Market was valued at $523.9 Million in 2026 and projected to reach to $733.1 Million by 2031, representing a compound annual growth rate of 7.0%. Mexico's plasma fractionation market is positioned for steady growth through 2031, supported by increasing prevalence of immunodeficiency disorders, bleeding disorders, and chronic diseases requiring plasma-derived therapies.

Mexico Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Mexico Plasma Fractionation Market Trends and Insights

  • Mexico's market growth is driven by increasing demand for immunoglobulin therapies, clotting factor concentrates, and albumin products across hospitals and specialty clinics.
  • The expansion reflects Mexico's strengthening healthcare infrastructure, rising prevalence of bleeding disorders and immunodeficiency conditions, and growing patient access to plasma-derived therapeutics. Mexico's plasma fractionation sector benefits from both domestic production capacity and strategic imports to meet clinical demand.
  • Mexico continues to invest in blood collection and processing facilities, supported by regulatory frameworks that align with international standards.
  • The market's 7.0% CAGR through 2031 underscores Mexico's role as a key player in Latin America's plasma fractionation landscape, with opportunities emerging from improved reimbursement policies and expanded hospital networks serving underserved populations..

Key Market Statistics

  • CAGR (2026-2031) 7.0% CAGR
  • Market Size, 2026 ~USD 523.9 Million
  • Forecast, 2031 ~USD 733.1 Million
  • Country Mexico

Mexico Plasma Fractionation Market Overview

Market Valuation Growth :

Mexico's plasma fractionation market is valued at USD 523.9 million in 2026 and is projected to reach USD 733.1 million by 2031, demonstrating robust expansion opportunities for stakeholders.

Consistent CAGR Performance :

The Mexican market is growing at a steady 7.0% CAGR from 2026 to 2031, slightly below the global average of 7.6%, indicating stable but competitive market dynamics.

Key Product Demand Drivers :

Immunoglobulin therapies, clotting factor concentrates, and albumin products are experiencing increased adoption across Mexican hospitals and specialty clinics, driven by rising patient needs.

Healthcare Infrastructure Expansion :

Mexico's growing healthcare sector and improving access to specialty treatments are creating favorable conditions for plasma fractionation product penetration and market consolidation.

Mexico Plasma Fractionation Market Dynamics

  • The expansion of specialty clinics and improved healthcare reimbursement policies are enhancing product accessibility across urban and emerging markets.
  • Rising awareness among healthcare providers about advanced immunoglobulin and clotting factor therapies is expected to drive adoption rates.
  • However, regulatory compliance and supply chain optimization remain critical factors for market participants seeking to capitalize on Mexico's growing demand for plasma fractionation products..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Mexico's plasma fractionation market is valued at USD 523.9 million in 2026 and will reach USD 733.1 million by 2031, growing at 7.0% CAGR.
      • Mexico's market expansion is fueled by rising demand for immunoglobulin and clotting factor therapies in hospitals and specialty care settings.
      • Mexico's healthcare infrastructure improvements and regulatory alignment support increased adoption of plasma-derived products.
      • Mexico's market growth reflects expanding patient access and emerging opportunities in reimbursement and hospital network expansion.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Mexico Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Plasma Fractionation Manufacturers : Manufacturers need Mexico-specific market data to assess market size, growth potential, and competitive positioning for product launches and capacity expansion decisions.
      • Healthcare Distributors & Suppliers : Distributors require detailed Mexico market insights to optimize inventory management, identify high-demand products, and negotiate supplier contracts effectively.
      • Hospital & Clinic Administrators : Healthcare facility leaders need market trends and product demand forecasts to make informed procurement decisions and budget planning for plasma-derived therapies.
      • Investment & Private Equity Firms : Investors seeking Mexico healthcare opportunities need comprehensive market analysis to evaluate acquisition targets, growth potential, and return on investment scenarios.
      • Regulatory & Policy Advisors : Policy professionals and regulatory consultants require Mexico-specific market data to inform healthcare policy recommendations and compliance strategy development.

      Reasons to Buy this Report

      • Market-Specific Sizing & Forecasts : Access precise valuation data for Mexico's plasma fractionation market with detailed 5-year projections (2026-2031), enabling accurate budget allocation and investment planning.
      • Competitive Landscape Intelligence : Understand Mexico-specific market dynamics, growth drivers, and regional barriers to entry that differentiate this market from global trends and other Latin American countries.
      • Product Demand Insights : Identify high-demand plasma fractionation products in Mexico including immunoglobulins, clotting factors, and albumin, with hospital and specialty clinic adoption patterns.
      • Strategic Market Entry Planning : Leverage Mexico-focused analysis to develop targeted go-to-market strategies, partnership opportunities, and distribution channel optimization for plasma-derived therapeutics.
      • Regulatory & Reimbursement Guidance : Gain insights into Mexico's healthcare reimbursement landscape and regulatory environment specific to plasma fractionation products, reducing market entry risks.

      Frequently asked questions

      What is the current size of Mexico's plasma fractionation market?

      Mexico's plasma fractionation market is valued at USD 523.9 million in 2026.

      What is the projected market size for Mexico's plasma fractionation sector by 2031?

      Mexico's plasma fractionation market is projected to reach USD 733.1 million by 2031.

      What is the growth rate of Mexico's plasma fractionation market?

      Mexico's plasma fractionation market is expected to grow at a CAGR of 7.0% from 2026 to 2031.

      What are the primary drivers of growth in Mexico's plasma fractionation market?

      Mexico's market growth is driven by increasing demand for immunoglobulin therapies, clotting factor concentrates, improved healthcare infrastructure, and expanded patient access to plasma-derived therapeutics.

      Which plasma fractionation products are most in demand in Mexico?

      Mexico shows strong demand for immunoglobulin therapies, clotting factor concentrates, and albumin products across hospitals and specialty clinics.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status